Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2008

Open Access 01-07-2008 | Preclinical Study

Central carbon metabolism in the progression of mammary carcinoma

Authors: Adam D. Richardson, Chen Yang, Andrei Osterman, Jeffrey W. Smith

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

There is a growing belief that the metabolic program of breast tumor cells could be a therapeutic target. Yet, without detailed information on central carbon metabolism in breast tumors it is impossible to know which metabolic pathways to target, and how their inhibition might influence different stages of breast tumor progression. Here we perform the first comprehensive profiling of central metabolism in the MCF10 model of mammary carcinoma, where the steps of breast tumor progression (transformation, tumorigenicity and metastasis) can all be examined in the context of the same genetic background. The metabolism of [U-13C]-glucose by a series of progressively more aggressive MCF10 cell lines was tracked by 2D NMR and mass spectrometry. From this analysis the flux of carbon through distinct metabolic reactions was quantified by isotopomer modeling. The results indicate widespread changes to central metabolism upon cellular transformation including increased carbon flux through the pentose phosphate pathway (PPP), the TCA cycle, as well as increased synthesis of glutamate, glutathione and fatty acids (including elongation and desaturation). The de novo synthesis of glycine increased upon transformation as well as at each subsequent step of breast tumor cell progression. Interestingly, the major metabolic shift in metastatic cells is a large increase in the de novo synthesis of proline. This work provides the first comprehensive view of changes to central metabolism as a result of breast tumor progression.
Appendix
Available only for authorised users
Literature
1.
go back to reference Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530CrossRefPubMed Warburg O, Wind F, Negelein E (1927) The metabolism of tumors in the body. J Gen Physiol 8:519–530CrossRefPubMed
2.
go back to reference Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–8930PubMedCrossRef Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 66:8927–8930PubMedCrossRef
3.
go back to reference Czernin J, Phelps ME (2002) Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89–112PubMedCrossRef Czernin J, Phelps ME (2002) Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89–112PubMedCrossRef
4.
go back to reference Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313:459–465PubMedCrossRef Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313:459–465PubMedCrossRef
5.
go back to reference Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:379–391PubMedCrossRef Miller FR (2000) Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5:379–391PubMedCrossRef
6.
go back to reference Soule HD, Maloney TM, Wolman SR et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075–6086PubMed Soule HD, Maloney TM, Wolman SR et al (1990) Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075–6086PubMed
7.
go back to reference Basolo F, Elliott J, Tait L et al (1991) Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 4:25–35PubMedCrossRef Basolo F, Elliott J, Tait L et al (1991) Transformation of human breast epithelial cells by c-Ha-ras oncogene. Mol Carcinog 4:25–35PubMedCrossRef
8.
go back to reference Dawson PJ, Wolman SR, Tait L et al (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148:313–319PubMed Dawson PJ, Wolman SR, Tait L et al (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 148:313–319PubMed
9.
go back to reference Santner SJ, Dawson PJ, Tait L et al (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65:101–110PubMedCrossRef Santner SJ, Dawson PJ, Tait L et al (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65:101–110PubMedCrossRef
10.
go back to reference Worsham MJ, Pals G, Schouten JP et al (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96:177–186PubMedCrossRef Worsham MJ, Pals G, Schouten JP et al (2006) High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96:177–186PubMedCrossRef
11.
go back to reference O’Neil KA, Miller FR, Barder TJ et al (2003) Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis. Proteomics 3:1256–1269PubMedCrossRef O’Neil KA, Miller FR, Barder TJ et al (2003) Profiling the progression of cancer: separation of microsomal proteins in MCF10 breast epithelial cell lines using nonporous chromatophoresis. Proteomics 3:1256–1269PubMedCrossRef
12.
go back to reference Maharjan RP, Ferenci T (2003) Global metabolite analysis: the influence of extraction methodology on metabolome profiles of Escherichia coli. Anal Biochem 313:145–154PubMedCrossRef Maharjan RP, Ferenci T (2003) Global metabolite analysis: the influence of extraction methodology on metabolome profiles of Escherichia coli. Anal Biochem 313:145–154PubMedCrossRef
13.
go back to reference Lee WN, Bassilian S, Guo Z et al (1994) Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. Am J Physiol 266:E372–E383PubMed Lee WN, Bassilian S, Guo Z et al (1994) Measurement of fractional lipid synthesis using deuterated water (2H2O) and mass isotopomer analysis. Am J Physiol 266:E372–E383PubMed
14.
go back to reference Wittmann C, Heinzle E (1999) Mass spectrometry for metabolic flux analysis. Biotechnol Bioeng 62:739–750PubMedCrossRef Wittmann C, Heinzle E (1999) Mass spectrometry for metabolic flux analysis. Biotechnol Bioeng 62:739–750PubMedCrossRef
15.
go back to reference Yang C, Richardson A, Smith J et al (2007) Comparative metabolomics of breast cancer. Pac Symp Biocomput 12:181–192CrossRef Yang C, Richardson A, Smith J et al (2007) Comparative metabolomics of breast cancer. Pac Symp Biocomput 12:181–192CrossRef
16.
go back to reference Forbes NS, Meadows AL, Clark DS et al (2006) Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab Eng 8:639–652PubMedCrossRef Forbes NS, Meadows AL, Clark DS et al (2006) Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab Eng 8:639–652PubMedCrossRef
17.
go back to reference Marshall S (2006) Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE (2006):re7 Marshall S (2006) Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE (2006):re7
18.
go back to reference Bauer DE, Harris MH, Plas DR et al (2004) Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18:1303–1305PubMed Bauer DE, Harris MH, Plas DR et al (2004) Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J 18:1303–1305PubMed
19.
go back to reference Kaplan O, Jaroszewski JW, Faustino PJ et al (1990) Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. J Biol Chem 265:13641–13649PubMed Kaplan O, Jaroszewski JW, Faustino PJ et al (1990) Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. J Biol Chem 265:13641–13649PubMed
20.
go back to reference Vizan P, Boros LG, Figueras A et al (2005) K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res 65:5512–5515PubMedCrossRef Vizan P, Boros LG, Figueras A et al (2005) K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Res 65:5512–5515PubMedCrossRef
21.
go back to reference Lee WN, Boros LG, Puigjaner J et al (1998) Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am J Physiol 274:E843–E851PubMed Lee WN, Boros LG, Puigjaner J et al (1998) Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am J Physiol 274:E843–E851PubMed
22.
go back to reference Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:3201S–3204SPubMed Conklin KA (2004) Cancer chemotherapy and antioxidants. J Nutr 134:3201S–3204SPubMed
23.
go back to reference Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267PubMedCrossRef Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267PubMedCrossRef
24.
go back to reference Kurosu T, Fukuda T, Miki T et al (2003) BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 22:4459–4468PubMedCrossRef Kurosu T, Fukuda T, Miki T et al (2003) BCL6 overexpression prevents increase in reactive oxygen species and inhibits apoptosis induced by chemotherapeutic reagents in B-cell lymphoma cells. Oncogene 22:4459–4468PubMedCrossRef
25.
go back to reference Nohl H, Gille L, Staniek K (1998) The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch [C] 53:279–285 Nohl H, Gille L, Staniek K (1998) The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch [C] 53:279–285
26.
go back to reference Yokomizo A, Ono M, Nanri H et al (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293–4296PubMed Yokomizo A, Ono M, Nanri H et al (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293–4296PubMed
27.
go back to reference Selak MA, Armour SM, MacKenzie ED et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85PubMedCrossRef Selak MA, Armour SM, MacKenzie ED et al (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7:77–85PubMedCrossRef
28.
go back to reference Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239PubMedCrossRef Pollard PJ, Briere JJ, Alam NA et al (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231–2239PubMedCrossRef
29.
go back to reference Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111–23115PubMedCrossRef Lu H, Forbes RA, Verma A (2002) Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem 277:23111–23115PubMedCrossRef
30.
go back to reference Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202–208PubMedCrossRef Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202–208PubMedCrossRef
31.
go back to reference Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–5980PubMedCrossRef Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–5980PubMedCrossRef
32.
go back to reference Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070–2075PubMedCrossRef Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW (2004) Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070–2075PubMedCrossRef
33.
go back to reference Yang YA, Morin PJ, Han WF et al (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132–137PubMedCrossRef Yang YA, Morin PJ, Han WF et al (2003) Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132–137PubMedCrossRef
34.
go back to reference Moon YA, Shah NA, Mohapatra S et al (2001) Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem 276:45358–45366PubMedCrossRef Moon YA, Shah NA, Mohapatra S et al (2001) Identification of a mammalian long chain fatty acyl elongase regulated by sterol regulatory element-binding proteins. J Biol Chem 276:45358–45366PubMedCrossRef
35.
go back to reference Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9:358–365PubMedCrossRef Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 9:358–365PubMedCrossRef
36.
go back to reference Pala V, Krogh V, Muti P et al (2001) Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 93:1088–1095PubMedCrossRef Pala V, Krogh V, Muti P et al (2001) Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 93:1088–1095PubMedCrossRef
37.
go back to reference Aclimandos WA, Heinemann D, Kelly SB et al (1992) Erythrocyte stearic to oleic acid ratio in patients with ocular melanoma. Eye 6(Pt 4):416–419PubMed Aclimandos WA, Heinemann D, Kelly SB et al (1992) Erythrocyte stearic to oleic acid ratio in patients with ocular melanoma. Eye 6(Pt 4):416–419PubMed
38.
go back to reference Scaglia N, Igal RA (2005) Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem 280:25339–25349PubMedCrossRef Scaglia N, Igal RA (2005) Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J Biol Chem 280:25339–25349PubMedCrossRef
Metadata
Title
Central carbon metabolism in the progression of mammary carcinoma
Authors
Adam D. Richardson
Chen Yang
Andrei Osterman
Jeffrey W. Smith
Publication date
01-07-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9732-3

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine